TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05661682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tralement
Description: Tralement with Manganese Sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose trace element combination product of zinc, copper, and selenious acid
Description: Tralement without Manganese Sulfate
Study: NCT06435936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose of SAB-176
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose of SAB-176
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose of SAB-176
Description: Single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose of SAB-176
Description: Single ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Ascending Dose of Placebo
Description: Single ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Ascending Dose of Placebo
Description: Single ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Ascending Dose of Placebo
Description: Single ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Ascending Dose of Placebo
Description: Single ascending dose
Study: NCT06288581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional toothbrush group
Description: Children in this group will use a traditional brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a U shaped brush with a traditional toothpaste for another 30 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: U shaped toothbrush group
Description: Children in this group will use a U shaped brush with a traditional toothpaste first to clean their teeth then after 30 days they will use a traditional brush with a traditional toothpaste for another 30 days.
Study: NCT06104228

Intervention type: DRUG
Group type: OTHER
Intervention: 129Xe Hyperpolarized
Description: Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490

Intervention type: DRUG
Group type: OTHER
Intervention: 129Xe Hyperpolarized
Description: Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490
Study: NCT05539625

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MitoQ
Description: MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis) MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05282550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trazodone
Description: 50mg of trazodone administered for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 50mg of trazodone administered for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 4 weeks.
Study: NCT06025916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: 20 ml of oral solution TA (100mg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 20 ml of oral solution TA (100mg/ml)
Study: NCT05176314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.
Study: NCT05543265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default appointment scheduling
Description: Default primary care appointment scheduling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted messaging
Description: Patient-specific messages about the importance of postpartum care transition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge Reminders
Description: Primary care appointment reminders
Study: NCT05318131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep and Lifestyle Advice Website
Description: Participants will be asked to view a website at least once a week for 3 months (remotely). The website includes information about exercise, nutrition and sleep. Participants will also have a check-in call with a health coach at 6 weeks, and will be sent email newsletters at approximately 1 and 2 months with additional information about sleep, nutrition, and exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys and Sleep Monitors
Description: At baseline and at 3 months, participants will be asked to complete online surveys and to wear an ActiGraph sleep monitor for one week. ActiGraph sleep monitors are wristbands that measure continuous sleep/wake activity information. The recorded ActiGraph data is deidentified and no individual personally identifiable information is collected. A unique serial number identifies each wrist monitor. At the end of the study, participants will also have a telephone exit interview with the study team to provide feedback on their progress during the study and about the website.
Study: NCT05568225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: 400 mg once daily
Study: NCT04530981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: Oral KIT/PDGFRA kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Oral antihyperglycemic agent
Study: NCT04736888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extended-reality CPR training
Description: extended-reality technologies based CPR training module

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional CPR training
Description: conventional CPR training with video
Study: NCT04854135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM4Home
Description: FreeStyle Libre 2 Continuous Glucose Monitoring System manufactured by Abbott
Study: NCT06050265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXCOM Continuous Glucose Monitor (CGM)
Description: Dexcom CGMs are placed every 10 days and provide a continuous assessment of blood glucose.
Study: NCT05590481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIBIAL TRANSCUTANEOUS ELECTROSTIMULATION
Description: The electrodes will be surface (silicone rubber and carbonate), brand Quark®, with dimensions of 5 cm by 3 cm, coupled with conductive gel and fixed to the volunteer's skin with micropore tape. For the placement of the electrodes, the volunteer will be positioned in the horizontal supine position on the stretcher, with the knee in semiflexion and the head supported on a pillow. The electrodes will be positioned one immediately posterior to the medial malleolus of the ankle and the other approximately 10 cm above it, both fixed with micropore tape, on both legs of the patient. To ensure that the electrodes stimulate the tibial nerve, a transcutaneous electrical nerve stimulation (TENS) current with a frequency of 1 Hz will first be applied, with a gradual increase in intensity, to verify a rhythmic movement of flexion of the hallux. The following parameters will be used for TTNS: frequency 10Hz (Hertz), pulse duration 200 μs (microseconds), for 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral therapy protocol
Description: submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: behavioral therapy protocol
Description: submitted to a behavioral therapy protocol, which involves bladder training, pelvic floor muscle training and modification of liquid intake. The orientation will be based on the initial evaluation of the patient, in which the responsible researcher will give verbal orientations and deliver booklets on the pathology, behavioral therapy and sleep hygiene.
Study: NCT05323695

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Depression Screening Intervention
Description: All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.
Study: NCT06462339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention Group
Description: The group that will receive pilates training via telerehabilitation
Study: NCT05137041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITP FIRTECH
Description: Infrared Therapy Patch
Study: NCT06383858

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening method
Description: All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening method
Description: In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1/PLGF was used to evaluate the risk of preeclampsia.
Study: NCT05908487

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AA Communities Speak to Healthcare Professionals
Description: The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AA Communities Speak to Healthcare Professionals
Description: The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AA Communities Speak to Healthcare Professionals
Description: The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AA Communities Speak to Healthcare Professionals
Description: The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.
Study: NCT06187896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: in this group,patients are treated with remimazolam and remifentanil for reduced sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: in this group,patients are treated with propofol and remifentanil for reduced sedation.
Study: NCT05533385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergenic extract
Description: In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
Study: NCT05595486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby2Home Mobile Application
Description: Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.
Study: NCT04647227

Intervention type: DRUG
Group type: OTHER
Intervention: coagulation factor VIIa [recombinant]-jncw
Description: a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
Study: NCT06579300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-1088
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ)
Description: Oral Capsule
Study: NCT05164120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belnacasan
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet containing 0mg of API
Study: NCT05762679

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Imaging
Description: Phase 1 is an imaging biomarker study.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Imaging
Description: Phase 1 is an imaging biomarker study.
Study: NCT06531395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiprubart
Description: humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiprubart
Description: humanized monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiprubart
Description: humanized monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sterile preservative-free solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile preservative-free solution
Study: NCT05583773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ShengXian-QuYu Decoction
Description: Specification: 30ml/bag, given twice daily, per oral use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching ShengXian-QuYu Decoction, 30ml/bag, given twice daily, per oral use.
Study: NCT05575830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine
Description: Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
Study: NCT06490900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Description: The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles (room air) to resaturation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intermittent normoxia
Description: The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air).
Study: NCT05983458

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transaortic valve replacement
Description: TAVI procedure will be performed under conscious sedation. Foley urinary catheters and jugular lines will be avoided.~For femoral access, closure devices will be Prostar or ProGlide, which are similar and carry low rates of major vascular complications . Single femoral access and a radial access as the secondary arterial access will be used to reduce the rate of vascular complications.~All procedures will be performed with cerebral protection using the Sentinel device. During valve implantation, commissural alignment will be checked for all patients. As a practical rule, commissural alignment will be checked in co-planar view and in cusp-overlap view.
Study: NCT06487572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study: NCT06205992

Intervention type: DEVICE
Intervention: 3D-MRE
Description: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.

Intervention type: DEVICE
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures

Intervention type: DEVICE
Intervention: 2D-MRE
Description: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.

Intervention type: DEVICE
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
Study: NCT05256901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or greater.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine/Glycopyrrolate
Description: Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
Study: NCT05381948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eyp-1901
Description: Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eyp-1901
Description: Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2Mg/0.05Ml Inj,Oph
Description: Intravitreal Injection
Study: NCT06268236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electro-acupuncture at Shuigou and Yintang.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham-EA at sham-Shuigou and sham-Yintang.
Study: NCT06581471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricuspid valve through a transcatheter approach
Study: NCT06581705

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: Evaluation of the success rates (SR) of anesthetists aged ≥45 years for intubating neonates and infants using the C-MAC videolaryngoscope (VL) in comparison to the use of the standard laryngoscope (SL).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: Evaluation of the success rates (SR) of anesthetists aged ≥45 years for intubating neonates and infants using the C-MAC videolaryngoscope (VL) in comparison to the use of the standard laryngoscope (SL).
Study: NCT05632640

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Following the participants procedure, standard of care will be given in the recovery area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted blanket
Description: Following the participants procedure once in the recovery area, the nursing staff will place a weighted blanket on the participants. Different weighted blanket sizes will be used based on participants weight.
Study: NCT05955911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 20 minutes of Moderate intensity (40%-59% heartrate reserve) walking on a treadmill.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Coloring
Description: 20 minutes of coloring in adult coloring book
Study: NCT04781478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of Biorepair Gel
Description: Professional application of Biorepair Gel after Scaling and Root Planing and Air-Perio polishing (glycine powders).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of Biorepair Gel
Description: Professional application of Biorepair Gel after Scaling and Root Planing and Air-Perio polishing (glycine powders).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation of Chlorhexidine 1.00% gel
Description: Irrigation of periodontal pockets with Chlorhexidine 1.00% gel afterScaling and Root Planing and Air-Perio polishing (glycine powders).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation of Chlorhexidine 1.00% gel
Description: Irrigation of periodontal pockets with Chlorhexidine 1.00% gel afterScaling and Root Planing and Air-Perio polishing (glycine powders).